Mitigate Toxicity with Combination Strategies & Gain Clarity on Regulatory Expectations to Select & Refine Patient Selection, Improving Trial Efficacy for Viral-Based Gene Therapies

Prioritize Safety, Maximize Efficacy, Improve Patient Access

The 6th Gene Therapy Immunogenicity Summit is an essential event for biotech and pharma companies looking to drive innovation and success in the rapidly evolving gene therapy landscape. Immunogenicity remains one of the most significant hurdles to the safe and effective development of gene therapies, particularly with challenges in:

Translational Medicine

Pharmacology

Non-Clinical Development

Toxicology

Clinical Development

Bioanalysis

By attending, you’ll join your peers and gain exclusive access to the latest scientific advancements, real-world case studies, and actionable strategies from industry pioneers.

This summit provides a unique platform to connect with experts, foster partnerships, and gain the critical insights needed to de-risk development pipelines, optimize therapeutic outcomes, and stay ahead in this highly competitive space.

World Class Speaker Faculty Includes:

2025 Sponsors:

agada biosciences

"The variety of topics was good with a mix of preclinical and clinical presentations. One of the things that made it most enjoyable was the small intimate setting and ability to talk with many attendees."

Sharon McGonigle, Vice President - R&D, Solid Biosciences

Logo-SolidBio
evox

"Very insightful talks broad enough to cover everything while still having depth. All the speakers were knowledgeable and the discussions were helpful."

Anna Ogbe, Group Leader - Translational, Clinical & Regulatory, Evox Therapeutics